Kronos Bio, Inc.
NASDAQ: KRON0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Deborah A. Knobelman
- Employees
- 8
- Headquarters
- San Mateo, United States
- IPO year
- 2020
- Market cap
- $53.7M
- Website
- https://kronosbio.com
Loading KRON…
Loading profile data…Frequently asked questions about KRON
What does Kronos Bio, Inc. (KRON) do?
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's prima...
Where does KRON trade?
Kronos Bio, Inc. (KRON) trades on the NASDAQ Global Select.
What sector is KRON in?
Kronos Bio, Inc. (KRON) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kronos Bio, Inc.?
Deborah A. Knobelman is the chief executive officer of Kronos Bio, Inc. (KRON).
Where is Kronos Bio, Inc. headquartered?
Kronos Bio, Inc. is headquartered in United States.
Does KRON pay a dividend?
Kronos Bio, Inc. (KRON) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KRON go public?
Kronos Bio, Inc. (KRON) completed its initial public offering in 2020.